Beacon Eye Gene Therapy Efforts Buoyed By Cash Boost

In a major boost for the UK biotech sector, an impressive sum has been raised by Beacon Therapeutics to support its R&D activities in ophthalmic gene therapies.

crowded field of eye gene therapies
• Source: Shutterstock

After a recent series B round, Beacon Therapeutics has boosted its finances by $170m, bringing its total funding to date to $290m, as it looks to advance in the crowded field of gene therapies for the eye.

The latest financing was led by Forbion and included existing investors Syncona, Oxford Science Enterprises and the University of Oxford,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

More from Therapeutic Category